Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

24SevenOffice Announces Launch of Strategic Partnership with Storebrand to Simplify Pension Management for Businesses

24SevenOffice is pleased to announce that it has launched a strategic partnership with Storebrand, one of the leading financial services providers in the Nordic region. This collaboration will allow 24SevenOffice to offer Storebrand’s pension solutions directly through its digital platform, further enhancing the value we provide to businesses and accounting firms.   As part of this partnership, 24SevenOffice has also been approved as a licensed ancillary insurance agent by the The Financial Supervisory Authority of Norway, enabling us to integrate Storebrand's pension products

Rejlers signs agreement with NYAB for project on Viskadalsbanan

Rejlers has signed an agreement with NYAB for an extensive infrastructure project on the Viskadalsbanan, the Borås-Varberg section. To ensure a reliable connection along the railway and improve the network's capacity, a new pipe system is now being installed to enable the installation of new fiber cables.In the Opto 2.0 railway project, the existing fibre cable, which is reaching the end of its technical life, will be replaced to ensure a stable and future-proof connection. This is of particular importance for the signalling systems along the railway. By installing a new multiduct, which

Interim Report Q2 – January – June, 2024 Redsense Medical AB (publ.)

April – June 2024 · Net sales amounted to kSEK 8,749 (4,831) · Operating profit, EBIT amounted to kSEK 613 (-3,045). · Result after tax amounted to kSEK 625 (2,966). · Earnings per share were SEK 0.04 (0.21). Significant events during the period · On April 24, The Board of Directors in Redsense resolved to carry out a directed share issue of approximately MSEK 9.8. · On May 22, Redsense announced that Discover Capital GmbH has sold all their shares in Redsense Medical AB (publ.) · On May 23, Redsense announced that ShapeQ GmbH has bought 750,000 shares

Ola Klingenborg appointed President of Coor in Sweden

Ola Klingenborg has been appointed President of Coor in Sweden, effective from the first quarter 2025, when he also joins the Executive Management Team.Ola’s most recent role was as President and CEO of the care company Team Olivia and he has a background from the media industry, working in companies like Clear Channel and Bonnier. Ola Klingenborg also has a background as a management consultant at McKinsey&Comapany. “I’m delighted that Ola has accepted the position as President of Coor in Sweden, a key role in driving the continued success of Coor. Ola is a strong leader with broad

NKT finalizes the Shetland HVDC Link supporting the transition to renewable energy of Great Britain

In close collaboration with SSEN Transmission, NKT has completed the turnkey project of connecting the Shetland Islands to the main grid in Scotland with the Shetland HVDC Link. The 320 kV HVDC interconnector is now a key contributor to the integration of renewable energy in Great Britain.Press Release29 August 2024  Interconnected power grids are essential to the green transition and with the completion of the Shetland HVDC Link 600 MW of renewable energy can now flow from the Shetland Islands to the Scottish mainland. NKT has finalized the turnkey project connecting the remote

Statement by the board of directors of Concentric in relation to the public offer from Circle BidCo

The board of directors of Concentric unanimously recommends Concentric’s shareholders to accept the public offer from Circle BidCo.   On August 29, 2024, Circle BidCo ApS (“Circle BidCo”), a wholly owned, indirect subsidiary of A.P. Møller Holding A/S, announced a public offer to the shareholders of Concentric AB (“Concentric” or the “Company”) to tender all their shares in the Company to Circle BidCo at a price of SEK 230 in cash per share (the “Offer”).   This statement regarding the Offer is made by the board of directors of Concentric pursuant to Rule II.19 of Nasdaq

BioStock: Curasight targets clinical proof-of-concept for uTREAT

Having secured financing for the ongoing clinical development of uTRACE, Curasight can now enter the next level in developing the therapeutic side of its theranostic approach. This will be done by rapidly achieving proof-of-concept in a single indication with uTREAT. BioStock contacted CEO Ulrich Krasilnikoff in conjunction with the Q2 report to learn more.Read the full article at biostock.se: https://www.biostock.se/en/2024/08/curasight-targets-clinical-proof-of-concept-for-utreat/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Investor appoints Jenny Ashman Haquinius as new Chief Financial Officer

Investor announced today that Jenny Ashman Haquinius, currently Principal at Patricia Industries, will become Chief Financial Officer (CFO) and member of the Executive Leadership Team during the fourth quarter of 2024. This follows the announcement on June 4, 2024, that the current CFO, Helena Saxon, will be leaving the company during the second quarter next year. Jenny Ashman Haquinius started at Investor in 2015 and has since contributed significantly in her roles, gaining solid knowledge of our portfolio companies, our engaged ownership model, as well as our work with new investments.

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2024

Second quarter (April-June 2024) · Operating profit/loss amounted to SEK -5,841,409 (-4 466 286). · Loss for the period amounted to SEK -5,622,779 (-4,335,852). · Cash flow from operating activities totalled SEK -7,733,270 (-2,146,178). · Earnings per share before and after dilution totalled SEK -0.16 (-0,22). Period (January-June 2024) · Operating profit/loss amounted to SEK -11,274,831 (-6,372,143). · Loss for the period amounted to SEK -10,992,456 (-6,602,181). · Cash flow from operating activities totalled SEK -16,997,666 (-4,181,989). · Earnings per share

Lytix Biopharma Q2 and H1 2024 results: Significant clinical advancements take Lytix Biopharma closer to commercialization

Oslo, 29 August 2024. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company dedicated to being part of tomorrow’s cancer treatment, today releases its second quarter and first half 2024 results. Lytix Biopharma is experiencing a pivotal shift for its lead drug candidates, marked by significant clinical progress.   Results from the Phase II study in patients with the skin cancer disease basal cell carcinoma (BCC) demonstrate that Lytix's lead drug candidate, LTX-315, achieved an 86% reduction in tumor size and complete elimination in over half of

Ponsse’s new solutions for sustainable harvesting on display at FinnMETKO

Ponsse will demonstrate new solutions at the FinnMETKO 2024 exhibition in Jämsä that support the daily activities of forest machine operators and help forest machine entrepreneurs monitor the profitability and productivity of their fleet. Ponsse’s new forwarders Elk and Wisend and H7 harvester heads will be showcased at the event for the first time.     In addition, we will present a material concept for fossil-free steel. Ponsse is the first forest machine manufacturer in the world which has part of its forest machine made from fossil-free steel produced by SSAB.We aim for a fossil-free

Q2 and half year report January – June 2024

Continued growth in invested assetsHighlights second quarter 2024 · Gross ERC at the end of June 2024 was EUR 314m (280 at December 2023) · Gross collections amounted to EUR 14.2m (20.3)* · Net collections amounted to EUR 12.0m (18.4)* · Cash EBITDA amounted to EUR 6.3m (13.8)* Highlights six months 2024 · Gross collections amounted to EUR 25.6m (30.3)* · Net collections amounted to EUR 21.6m (26.4)* · Cash EBITDA amounted to EUR 11.7m (18.2)* · Erik Fällström appointed as CEO, replacing Razvan Munteanu Significant events after the end of the quarter ·

Monthly Update – July 2024

29 August 2024 Ashoka WhiteOak Emerging Markets Trust plc (the "Company") Monthly Update – July 2024 The Company's quarterly factsheet as at 31 July 2024 is now available: https://awemtrust.com/factsheet/ The Company’s NAV was down 1.6% in July 2024, underperforming the MSCI EM index by 33bps. Key contributors for July 2024 include Awfis Space Solutions (+32.5%, leading co-working space company in India), Alibaba Group Holding (+7.8%, amongst the biggest e-commerce companies in the world), and CAMS (+23.6%, India’s largest services provider to mutual funds).   Notable

Esmaeilzadeh Holding publishes interim report for the period January - June 2024

“ We are focused on completing ongoing processes to strengthen EHAB’s balance sheet and create the conditions for the company’s next phase. Our previous goal of achieving a net asset value of 27 BSEK by the end of the fiscal year 2027 is now subordinate to our priority of adjusting the balance sheet to the current market conditions. Once these processes are completed, our ambition is to be able to present an updated strategic direction that continues to reflect our core values. The investment portfolio generally shows strong cash flows, despite certain segments being affected by a weaker

MEKO in new partnership to strengthen its sustainability efforts

MEKO strengthens its sustainability efforts through a new partnership with Worldfavor, a digital platform that enables transparent data access. The partnership aims to further improve the clarity of MEKO's supply chain, ensuring a sustainable and transparent network for suppliers, producers and employees.The goal is to cover the entire supply base, including both centrally managed suppliers and those handled locally within different business areas. This platform will enhance transparency across MEKO's operations and optimize its sustainability efforts. "We recognized the need for a

Interim Financial Report – first six months of 2024 (Q2 2024)

Company announcement from SGL Group ApS 29 August 2024 - Company announcement no. 18  Q2 2024 results: Performance in line with the market and delivered growth in volumes Today, SGL Group ApS has published its Interim Financial Report for the first six months of 2024 (Q2 2024). SGL performed in line with the market and delivered growth in volumes in Air & Ocean, materialising in higher revenue and gross profit compared to previous quarter. However, due to a challenging environment we are yet to materialise full scale in North America. · Revenue amounted to EUR 532m in Q2

Arctic Bioscience - Study de-risked by all needed patients passed 6 months, read-out expected in 4-6 weeks

Highlights H1 2024: · The HeROPA clinical trial fully recruited in January 2024 and proceeding as planned, de-risked by sufficient number of patients has passed the 6 months milestone · 6-months primary end-point read-out is expected ultimo September/early October · Recently published mode-of-action research showed positive effects on cells related to resolution of inflammation of phospholipid esters from HRO350 · Nutra revenues in H1 2024 totalling NOK 16,7 million (NOK 19,1 million). Revenue prospects for H2 2024 are positive · Booked sales and received purchase orders at

Cereno Scientific publishes the interim report for Q2 2024 (April 1–June 30)

The Board and Chief Executive Officer of Cereno Scientific AB here present the interim report for Q2 2024 (April 1–June 30).Summary of the interim report for Q2 2024 (April 1–June 30) Cereno Scientific Group · Net Sales were SEK 0 (0) · Result after financial items was SEK -21,234,039 (-10,686,053) · Earnings per share was SEK -0.08 (-0.05) before dilution and SEK -0.01 (-0.04) after dilution · The equity/assets ratio was 76.2% (95.4%) · Cash and bank balance was SEK 85,596,493 (85,291,722) Parent company · Net Sales were SEK 0 (0) · Result after financial

Interim Report for the period April – June 2024

Lecanemab authorised in Great Britain and EU re-examination in progress Events during the second quarter 2024 · BioArctic and Eisai entered into a research evaluation agreement regarding the drug candidate BAN2802 · Eisai received Fast Track designation and initiated a rolling Biologics License Application (BLA) to the FDA for subcutaneous maintenance dosing of Leqembi[®] · Eisai published sales projection for Leqembi for fiscal year 2024 (April 2024 – March 2025) of JPY 56.5 billion · The U.S. Food and Drug Administration (FDA) accepted Eisai’s Supplemental Biologics

Bonava and OBOS form partnership to develop 200 housing units in Gothenburg

Bonava has formed a partnership with OBOS Nya Hem to jointly develop the Explora block in Södra Änggården, Gothenburg. The partnership will involve the transfer by Bonava of 200 building rights to a joint venture for which it will receive a payment of SEK 65 M during the third quarter.– We are delighted to have established a structure for a long-term collaboration with OBOS Nya Hem. Together we can leverage our combined expertise and be a leading player in the development of this exciting city district. We also hope this will lead to new, similar partnerships in the future. This also means

Circle BidCo announces a recommended public cash offer of SEK 230 per share to the shareholders of Concentric

This announcement is not an offer, whether directly or indirectly, in Australia, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important information” at the end of this announcement and in

Greenfood’s Interim report second quarter 2024

Greenfood has released its interim report for the second quarter of 2024, delivering on strategic priorities with a 20.9% earnings growth.· Net sales for the quarter totaled SEK 1,525.6 million (1,524.4), a marginal increase of 0.1 percent, with Fresh Produce down -7.1 percent due to low business activity in food service and consumers trading down to more affordable options. Picadeli and Food Solutions maintained expected momentum, growing by 10.0 and 7.3 percent, respectively.  · Adjusted EBITDA of SEK 120.0 million (99.3) was significantly better than Q2 2023. The increase of SEK 20.

There are no items matching the current filter
There are no more items matching the current filter
Back to top